Marshall Edwards Licenses the Investigational Anti-Cancer Compound NV-128 From Novogen Limited
05 août 2009 08h05 HE
|
Marshall Edwards, Inc.
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - August 5, 2009) - Novogen Limited (ASX: NRT) (NASDAQ: NVGN) and Marshall Edwards, Inc. (NASDAQ: MSHL) have
concluded a license agreement for...
Novogen's NV-128, a Novel mTOR Inhibitor, Shows Potential Activity Against Cancer Stem Cells
01 déc. 2008 08h10 HE
|
NOVOGEN LIMITED
SYDNEY, AUSTRALIA and NEW CANAAN, CT--(Marketwire - December 1, 2008) - Pharmaceutical company
Novogen Limited (NASDAQ: NVGN) (ASX: NRT) today announced that work
performed in collaboration with a...
Marshall Edwards' Phenoxodiol and Novogen's NV-128 Display Divergent Mechanisms of Action but Potent Synergistic Anti-Cancer Activity When Used in Combination
30 oct. 2008 19h19 HE
|
Novogen, Limited
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - October 30, 2008) - Pre-clinical studies
presented at the 9th International Conference on Membrane Redox Systems in
Wellington New Zealand this...
Novogen's NV-128 Is a Unique Inhibitor of mTOR Dephosphorylation Leading to Caspase Independent Death in Chemoresistant Cancer Cells
15 avr. 2008 17h25 HE
|
Novogen, Limited
SAN DIEGO, CA--(Marketwire - April 15, 2008) - Pre-clinical studies reviewed during an oral
presentation here today at the annual meeting of the American Association
for Cancer Research demonstrate...
Yale Researchers to Present Data at AACR Conference Indicating That Novogen Compound NV-128 Uses mTOR Pathway to Induce Cell Death in Chemo-Resistant Ovarian Cancer Cells
25 mars 2008 08h01 HE
|
NOVOGEN LIMITED
SYDNEY, AUSTRALIA and NEW CANAAN, CT--(Marketwire - March 25, 2008) - An abstract for an
oral presentation to be given at the Annual Meeting of the American
Association for Cancer Research, April 12...
Novogen NV-128 Induces Novel Mode of Cell Death in Cancer Cells
24 oct. 2007 08h07 HE
|
Novogen
SAN FRANCISCO, CA--(Marketwire - October 24, 2007) - Laboratory studies presented late
yesterday at the annual AACR/EORTC/NCI Molecular Targets and Cancer
Therapeutics conference demonstrate that...